Cargando…
Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach
In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paire...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249157/ https://www.ncbi.nlm.nih.gov/pubmed/22033876 http://dx.doi.org/10.1007/s00401-011-0893-0 |
_version_ | 1782220299640504320 |
---|---|
author | Thomas, Stefani N. Funk, Kristen E. Wan, Yunhu Liao, Zhongping Davies, Peter Kuret, Jeff Yang, Austin J. |
author_facet | Thomas, Stefani N. Funk, Kristen E. Wan, Yunhu Liao, Zhongping Davies, Peter Kuret, Jeff Yang, Austin J. |
author_sort | Thomas, Stefani N. |
collection | PubMed |
description | In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paired helical filaments were isolated from AD brain and subjected to nanoflow liquid chromatography–tandem mass spectrometry analysis. The resulting spectra identified monomethylation of lysine residues as a new tau modification. The methyl-lysine was distributed among seven residues located in the projection and microtubule binding repeat regions of tau protein, with one site, K254, being a substrate for a competing lysine modification, ubiquitylation. To characterize methyl lysine content in intact tissue, hippocampal sections prepared from post mortem late-stage AD cases were subjected to double-label confocal fluorescence microscopy using anti-tau and anti-methyl lysine antibodies. Anti-methyl lysine immunoreactivity colocalized with 78 ± 13% of neurofibrillary tangles in these specimens. Together these data provide the first evidence that tau in neurofibrillary lesions is post-translationally modified by lysine methylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-011-0893-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3249157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-32491572012-01-11 Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach Thomas, Stefani N. Funk, Kristen E. Wan, Yunhu Liao, Zhongping Davies, Peter Kuret, Jeff Yang, Austin J. Acta Neuropathol Original Paper In sporadic Alzheimer’s disease (AD), neurofibrillary lesion formation is preceded by extensive post-translational modification of the microtubule associated protein tau. To identify the modification signature associated with tau lesion formation at single amino acid resolution, immunopurified paired helical filaments were isolated from AD brain and subjected to nanoflow liquid chromatography–tandem mass spectrometry analysis. The resulting spectra identified monomethylation of lysine residues as a new tau modification. The methyl-lysine was distributed among seven residues located in the projection and microtubule binding repeat regions of tau protein, with one site, K254, being a substrate for a competing lysine modification, ubiquitylation. To characterize methyl lysine content in intact tissue, hippocampal sections prepared from post mortem late-stage AD cases were subjected to double-label confocal fluorescence microscopy using anti-tau and anti-methyl lysine antibodies. Anti-methyl lysine immunoreactivity colocalized with 78 ± 13% of neurofibrillary tangles in these specimens. Together these data provide the first evidence that tau in neurofibrillary lesions is post-translationally modified by lysine methylation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00401-011-0893-0) contains supplementary material, which is available to authorized users. Springer-Verlag 2011-10-28 2012 /pmc/articles/PMC3249157/ /pubmed/22033876 http://dx.doi.org/10.1007/s00401-011-0893-0 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Paper Thomas, Stefani N. Funk, Kristen E. Wan, Yunhu Liao, Zhongping Davies, Peter Kuret, Jeff Yang, Austin J. Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title | Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title_full | Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title_fullStr | Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title_full_unstemmed | Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title_short | Dual modification of Alzheimer’s disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
title_sort | dual modification of alzheimer’s disease phf-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249157/ https://www.ncbi.nlm.nih.gov/pubmed/22033876 http://dx.doi.org/10.1007/s00401-011-0893-0 |
work_keys_str_mv | AT thomasstefanin dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT funkkristene dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT wanyunhu dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT liaozhongping dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT daviespeter dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT kuretjeff dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach AT yangaustinj dualmodificationofalzheimersdiseasephftauproteinbylysinemethylationandubiquitylationamassspectrometryapproach |